{
    "2018-02-19": [
        [
            {
                "time": "2018-01-03",
                "original_text": "These 3 Stocks Just Raised Their Dividends",
                "features": {
                    "keywords": [
                        "dividends",
                        "raised"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "AbbVie Presents New Data on Upadacitinib for Crohn's Disease",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Crohn's Disease",
                        "data"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "6 Notable Dividend Stocks Boost Payouts, Including Coca-Cola (KO)",
                "features": {
                    "keywords": [
                        "dividend",
                        "boost",
                        "Coca-Cola"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "consumer goods"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Analystsâ€™ Recommendations for Merck & Co. after 4Q17",
                "features": {
                    "keywords": [
                        "analysts",
                        "recommendations",
                        "Merck",
                        "4Q17"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "AbbVie Presents New Data on Upadacitinib for Crohn's Disease",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Crohn's Disease",
                        "data"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Is AbbVie or Gilead Sciences Stock a Better Buy?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Gilead Sciences",
                        "better buy"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Cosentyx May Change Disease Progression for Ankylosing Spondylitis",
                "features": {
                    "keywords": [
                        "Cosentyx",
                        "disease progression",
                        "Ankylosing Spondylitis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}